biological source
rabbit
conjugate
unconjugated
antibody form
affinity isolated antibody
antibody product type
primary antibodies
clone
polyclonal
form
buffered aqueous solution
mol wt
antigen 43 kDa
species reactivity
human, rat, mouse
concentration
~1 mg/mL
technique(s)
ELISA: 1:10000, immunohistochemistry: 1:50-1:100, western blot: 1:500-1:1000
NCBI accession no.
UniProt accession no.
shipped in
wet ice
storage temp.
−20°C
target post-translational modification
phosphorylation (pSer15)
Quality Level
Gene Information
human ... TP53(7157)
General description
TP53 (tumor protein p53) gene is located on human chromosome 17p13.1. This is a tumor-suppressor gene.
Immunogen
The antiserum was produced against synthesized peptide derived from human p53 around the phosphorylation site of Ser15.
Immunogen Range: 1-50
Immunogen Range: 1-50
Biochem/physiol Actions
TP53 (tumor protein p53) gene is required for the DNA-damage checkpoint.This protein controls cell cycle, senescence and apoptosis upon oncogene activation, stress and DNA damage. Mutation in TP53 results in breast cancer.
Features and Benefits
Evaluate our antibodies with complete peace of mind. If the antibody does not perform in your application, we will issue a full credit or replacement antibody. Learn more.
Physical form
Rabbit IgG in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
未找到合适的产品?
试试我们的产品选型工具.
存储类别
10 - Combustible liquids
wgk
WGK 1
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
低风险生物材料
常规特殊物品
此项目有
Assessing TP53 status in human tumours to evaluate clinical outcome.
Soussi T and Beroud C
Nature Reviews. Cancer, 1(3), 233-233 (2001)
Wip1 phosphatase: between p53 and MAPK kinases pathways.
Goloudina AR, et al.
Oncotarget, 7(21), 31563-31571 (2016)
TP53 mutations and protein immunopositivity may predict for poor outcome but also for trastuzumab benefit in patients with early breast cancer treated in the adjuvant setting.
Fountzilas G, et al.
Oncotarget, 7(22), 32731-32753 (2016)
我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持